Rajesh Krishnamurthy
Research Subjects
Rajesh Krishnamurthy has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Danny K. Chou
Center for Pharmaceutical Biotechnology, University of Colorado Denver Health Sciences Center, Aurora, Colorado, USA
3 shared publicationsTheodore W. Randolph
Center for Pharmaceutical Biotechnology, University of Colorado, Boulder, Colorado
3 shared publicationsDimki Patel
Zyngenia, Inc.; Gaithersburg, MD USA
2 shared publicationsErnest Boyd
Zyngenia, Inc.; Gaithersburg, MD USA
2 shared publicationsGeping Wang
Zyngenia, Inc.; Gaithersburg, MD USA
2 shared publications- John F. Carpenter
Department of Pharmaceutical Sciences, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, 80045
2 shared publications
Latest Publications
- 1 March 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (3) , 842-851
Protein Covalent Dimer Formation Induced by Reversed-Phase HPLC Conditions
- 1 March 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (3) , 842-851
Protein Covalent Dimer Formation Induced by Reversed-Phase HPLC Conditions
- Open Access
- 1 March 2013
- Published by Taylor & Francis in mAbs
- Vol. 5 (2) , 208-218
Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides
The recognition that few human diseases are thoroughly addressed by mono-specific, monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics with additional specificities and enhanced activity. Historically, efforts to engineer additional antigen recognition into molecules have relied predominantly on the reformatting of immunoglobulin domains. In this report we describe a series of fully functional mAbs to which additional specificities have been imparted through the recombinant fusion of relatively short polypeptides sequences. The sequences are selected for binding to a particular target from combinatorial libraries that express linear, disulfide-constrained, or domain-based structures. The potential for fusion of peptides to the N- and C- termini of both the heavy and light chains affords the bivalent expression of up to four different peptides. The resulting molecules, called zybodies, can gain up to four additional specificities, while retaining the original functional...
- 1 March 2013
- Published by Taylor & Francis in mAbs
- Vol. 5 (2) , 208-218
Open AccessMonoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides
The recognition that few human diseases are thoroughly addressed by mono-specific, monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics with additional specificities and enhanced activity. Historically, efforts to engineer additional antigen recognition into molecules have relied predominantly on the reformatting of immunoglobulin domains. In this report we describe a series of fully functional mAbs to which additional specificities have been imparted through the recombinant fusion of relatively short polypeptides sequences. The sequences are selected for binding to a particular target from combinatorial libraries that express linear, disulfide-constrained, or domain-based structures. The potential for fusion of peptides to the N- and C- termini of both the heavy and light chains affords the bivalent expression of up to four different peptides. The resulting molecules, called zybodies, can gain up to four additional specificities, while retaining the original functional...
- 1 February 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (2) , 660-673
Effects of Solution Conditions on Methionine Oxidation in Albinterferon Alfa-2b and the Role of Oxidation in its Conformation and Aggregation
- 1 February 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (2) , 660-673
Effects of Solution Conditions on Methionine Oxidation in Albinterferon Alfa-2b and the Role of Oxidation in its Conformation and Aggregation
- Open Access
- 1 September 2012
- Published by Taylor & Francis in mAbs
- Vol. 4 (5) , 600-613
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
Despite the clinical success of anti-tumor necrosis factor (TNF) therapies in the treatment of inflammatory conditions such as rheumatoid arthritis, Crohn disease and psoriasis, full control of the...
- 1 September 2012
- Published by Taylor & Francis in mAbs
- Vol. 4 (5) , 600-613
Open AccessSimultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
Despite the clinical success of anti-tumor necrosis factor (TNF) therapies in the treatment of inflammatory conditions such as rheumatoid arthritis, Crohn disease and psoriasis, full control of the...
- 1 August 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (8) , 2702-2719
Physical Stability of Albinterferon-α2b in Aqueous Solution: Effects of Conformational Stability and Colloidal Stability on Aggregation
- 1 August 2012
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (8) , 2702-2719
Physical Stability of Albinterferon-α2b in Aqueous Solution: Effects of Conformational Stability and Colloidal Stability on Aggregation
- 1 September 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (9) , 3058-3071
Quantitation of protein particles in parenteral solutions using micro-flow imaging
- 1 September 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (9) , 3058-3071
Quantitation of protein particles in parenteral solutions using micro-flow imaging
- 20 December 2006
- Published by Springer Nature in Pharmaceutical Research
- Vol. 24 (2) , 370-376
Influence of Processing Conditions on the Physical State of Mannitol—Implications in Freeze-Drying
Purpose To study the effect of processing conditions on the physical state of mannitol during various stages of the lyophilization cycle of a protein formulation. Materials and Methods Mannitol and trehalose were used as the bulking agent and lyoprotectant, respectively. The physical state of mannitol during various stages of freeze-drying cycle, in the absence and presence of a model protein, was characterized using low temperature X-ray powder diffractometry (XRD) and differential scanning calorimetry (DSC). Results Mannitol did not crystallize even when the solution for lyophilization was cooled to −45°C at a slow cooling rate of 1°C/min. Annealing facilitated mannitol crystallization, and in the absence of the protein, a mixture of δ-mannitol and mannitol hemihydrate was obtained at both low (−18°C) and high (−8°C) annealing temperatures. However, in the presence of protein, the high annealing temperature promoted δ-mannitol crystallization and inhibited formation of mannitol hemihydrate, while the low annealing temperature facilitated the formation of mannitol hemihydrate. Interestingly, the hemihydrate in the frozen solution was retained in the final lyophile, even when the primary and secondary drying temperatures were as high as −5 and 65°C, respectively. Conclusions The presence of protein as well as the processing conditions (annealing temperature and time, primary and secondary drying temperatures) influenced the physical form of mannitol in the final lyophile. The protein promoted formation of δ-mannitol while inhibiting the formation of mannitol hemihydrate. Since the physical form of mannitol was greatly influenced by the presence of protein, it will be prudent to conduct the preliminary lyophilization cycle development studies in the presence of the protein. If mannitol hemihydrate is formed during annealing, its dehydration may require high secondary drying temperature.
- 20 December 2006
- Published by Springer Nature in Pharmaceutical Research
- Vol. 24 (2) , 370-376
Influence of Processing Conditions on the Physical State of Mannitol—Implications in Freeze-Drying
Purpose To study the effect of processing conditions on the physical state of mannitol during various stages of the lyophilization cycle of a protein formulation. Materials and Methods Mannitol and trehalose were used as the bulking agent and lyoprotectant, respectively. The physical state of mannitol during various stages of freeze-drying cycle, in the absence and presence of a model protein, was characterized using low temperature X-ray powder diffractometry (XRD) and differential scanning calorimetry (DSC). Results Mannitol did not crystallize even when the solution for lyophilization was cooled to −45°C at a slow cooling rate of 1°C/min. Annealing facilitated mannitol crystallization, and in the absence of the protein, a mixture of δ-mannitol and mannitol hemihydrate was obtained at both low (−18°C) and high (−8°C) annealing temperatures. However, in the presence of protein, the high annealing temperature promoted δ-mannitol crystallization and inhibited formation of mannitol hemihydrate, while the low annealing temperature facilitated the formation of mannitol hemihydrate. Interestingly, the hemihydrate in the frozen solution was retained in the final lyophile, even when the primary and secondary drying temperatures were as high as −5 and 65°C, respectively. Conclusions The presence of protein as well as the processing conditions (annealing temperature and time, primary and secondary drying temperatures) influenced the physical form of mannitol in the final lyophile. The protein promoted formation of δ-mannitol while inhibiting the formation of mannitol hemihydrate. Since the physical form of mannitol was greatly influenced by the presence of protein, it will be prudent to conduct the preliminary lyophilization cycle development studies in the presence of the protein. If mannitol hemihydrate is formed during annealing, its dehydration may require high secondary drying temperature.
- 31 August 2005
- Published by Springer Nature in Pharmaceutical Research
- Vol. 22 (11) , 1978-1985
Influence of the Active Pharmaceutical Ingredient Concentration on the Physical State of Mannitol—Implications in Freeze-Drying
The aim of this study was to investigate the effect of the concentration of the active pharmaceutical ingredient on the physical state of mannitol in frozen aqueous systems. A human monoclonal antibody was used as the model protein. Mannitol and sucrose were used as the bulking agent and the lyoprotectant, respectively. The thermal behavior of frozen mannitol–sucrose solutions during and after annealing, in the absence and presence of the protein, were characterized by low-temperature powder X-ray diffractometry and differential scanning calorimetry. The influence of the protein on the crystallization behavior of mannitol was also evaluated. The excipient concentration had a pronounced effect on the glass transition temperature of maximally freeze-concentrated amorphous phase (T g′). At fixed excipient compositions, the protein had no effect on the T g′ if the protein concentration was ≤20 mg/ml. However, at higher protein concentrations, there was a marked increase in T g′ as a function of protein concentration. The inhibitory effect of the protein on mannitol crystallization was concentration dependent and was directly evident from X-ray diffractometry experiments. Annealing facilitated both mannitol nucleation and crystal growth even in the presence of the protein. The ratio of mannitol to sucrose and the protein concentration have an impact on the T g′ and may therefore influence the primary drying temperature. The protein inhibits both the nucleation and growth of mannitol crystals and this effect seems to be concentration dependent. The presence of the protein and the protein concentration dictate the processing conditions, i.e., annealing time, annealing temperature, and primary drying temperature.
- 31 August 2005
- Published by Springer Nature in Pharmaceutical Research
- Vol. 22 (11) , 1978-1985
Influence of the Active Pharmaceutical Ingredient Concentration on the Physical State of Mannitol—Implications in Freeze-Drying
The aim of this study was to investigate the effect of the concentration of the active pharmaceutical ingredient on the physical state of mannitol in frozen aqueous systems. A human monoclonal antibody was used as the model protein. Mannitol and sucrose were used as the bulking agent and the lyoprotectant, respectively. The thermal behavior of frozen mannitol–sucrose solutions during and after annealing, in the absence and presence of the protein, were characterized by low-temperature powder X-ray diffractometry and differential scanning calorimetry. The influence of the protein on the crystallization behavior of mannitol was also evaluated. The excipient concentration had a pronounced effect on the glass transition temperature of maximally freeze-concentrated amorphous phase (T g′). At fixed excipient compositions, the protein had no effect on the T g′ if the protein concentration was ≤20 mg/ml. However, at higher protein concentrations, there was a marked increase in T g′ as a function of protein concentration. The inhibitory effect of the protein on mannitol crystallization was concentration dependent and was directly evident from X-ray diffractometry experiments. Annealing facilitated both mannitol nucleation and crystal growth even in the presence of the protein. The ratio of mannitol to sucrose and the protein concentration have an impact on the T g′ and may therefore influence the primary drying temperature. The protein inhibits both the nucleation and growth of mannitol crystals and this effect seems to be concentration dependent. The presence of the protein and the protein concentration dictate the processing conditions, i.e., annealing time, annealing temperature, and primary drying temperature.
- 1 June 2005
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 94 (6) , 1368-1381
Effects of Tween 20® and Tween 80® on the Stability of Albutropin During Agitation
- 1 June 2005
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 94 (6) , 1368-1381
Effects of Tween 20® and Tween 80® on the Stability of Albutropin During Agitation
- 1 December 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 3 (4) , 361-371
The Stability Factor: Importance in Formulation Development
Efficient development of stable formulations of protein pharmaceuticals requires an intimate knowledge of the protein and its chemical and physical properties. In particular, understanding the mechanisms by which a protein could degrade is critical for designing and testing formulations. This review describes the major pathways by which proteins can degrade, including denaturation, aggregation, oxidation, and interfacial damage. The methods to detect the degradation are covered, along with generalized strategies to retard or prevent each type of decomposition. Without an appreciation of the current best practices for devising stable formulations, the formulation process will be neither efficient nor optimal.
- 1 December 2002
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 3 (4) , 361-371
The Stability Factor: Importance in Formulation Development
Efficient development of stable formulations of protein pharmaceuticals requires an intimate knowledge of the protein and its chemical and physical properties. In particular, understanding the mechanisms by which a protein could degrade is critical for designing and testing formulations. This review describes the major pathways by which proteins can degrade, including denaturation, aggregation, oxidation, and interfacial damage. The methods to detect the degradation are covered, along with generalized strategies to retard or prevent each type of decomposition. Without an appreciation of the current best practices for devising stable formulations, the formulation process will be neither efficient nor optimal.